Roivant Sciences Ltd

NASDAQ:ROIV   3:59:52 PM EDT
8.83
-0.06 (-0.68%)
4:12:01 PM EDT: $8.10 -0.73 (-8.27%)
Earnings Announcements

Roivant Sciences Reports Financial Results And Provides Business Update

Published: 11/15/2021 12:35 GMT
Roivant Sciences Ltd (ROIV) - Roivant Sciences Reports Financial Results for the Quarter Ended September 30, 2021 and Provides Business Update.
Roivant Sciences Ltd - Qtrly Loss per Share $0.32.
Roivant Sciences Ltd - in Addition to Studies Underway at Dermavant, Expect at Least Four Other Programs Will Enter Phase 2 Or Phase 3 Trials in 2022.
Revenue is expected to be $7.57 Million
Adjusted EPS is expected to be -$0.24

Next Quarter Revenue Guidance is expected to be $7.64 Million
Next Quarter EPS Guidance is expected to be -$0.25

More details on our Analysts Page.